We conducted a single center retrospective cohort study on hospitalized patients with
severe acute respiratory syndrome coronavirus type 2 infection who received treatment
with nimatevir/ritonavir tablets or azivudine tablets at the First Affiliated Hospital of
Shandong First Medical University from December 1，2022 to January 31，2023. In the
research of this project, it is necessary to extract, sort out and retrospectively
analyze the clinical data of all patients with COVID-19 who have received
Nematovir/Ritonavir tablets or Azivudine tablets in the First Affiliated Hospital of
Shandong First Medical University (Shandong Qianfoshan Hospital), and respectively
identify the relevant epidemiological characteristics of COVID-19 patients, It is planned
to use multiple linear regression or logical regression model to explore the relevant
factors that affect the drug use efficiency index, safety index and total cost of
patients with COVID-19, so as to provide scientific and quantitative evidence support for
the drug use mode of the disease, the clinical value of the drug and the rational drug
use of patients, and also provide favorable basis for the supervision and decision-making
of smart pharmacy of medical institutions.